Ajinomoto Althea and OmniChem, global leaders in large and small molecule contract manufacturing services, announced that they are integrating their businesses and operations as a unified Contract Development and Manufacturing Organization (CDMO), and changing their name to Ajinomoto Bio-Pharma Services.
The name change reflects the unified company’s commitment to providing its large and small molecule clients accessibility to a broader range of service offerings. Ajinomoto Bio-Pharma Services includes small molecule manufacturing, formerly OmniChem’s Pharmaceutical Custom Manufacturing division (Wetteren and Balen, Belgium), and large molecule manufacturing and aseptic fill finish services, formally Althea (San Diego, United States). In 2019, Ajinomoto Co.’s oligonucleotide manufacturing entity, GeneDesign (Osaka, Japan), will join Ajinomoto Bio-Pharma Services.
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates.
The company offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including: Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Founded in 1909 and it is now operating in 30 countries.
Mr. Jason Tham, CEO at Nulogy, commented
“In today’s volatile market driven by shifting consumer preferences, omni-channel, and retail disruption, companies have to be more agile than ever to take advantage of market opportunities. We’re seeing the world’s largest and fastest growing consumer goods companies take a hard look at their supply chains and assess how they can leverage them to become more agile and responsive.”